Gilead Acquires CymaBay: Liver Cure Leap?
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
- Latest
- Trending
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
Canadian asset management firm AGF Management has made a strategic investment in New York-based investment manager New Holland Capital as ...
San Francisco-based AI and cybersecurity company, Reken, has raised $10 million in a Seed funding round led by Greycroft and ...
Dogecoin is losing ground as investors shift focus to FLOKI and NuggetRush, newer meme coins with greater potential for growth ...
Popular crypto strategist DonAlt believes that Ethereum (ETH) is on the brink of a major surge, potentially reaching prices not ...
SU Group Holdings Limited announces a prestigious security system contract in Hong Kong, showcasing their expertise and potential for growth.
Martin Marietta Materials is set to acquire 20 aggregates operations from Blue Water Industries for $2.05 billion, expanding its footprint ...
The Dow Jones ends the week with minimal changes, while the Nasdaq approaches a record high. Fed officials highlight the ...
Actively managed strategies and AI investments are fueling growth in the ETF industry. The industry is expanding its offerings and ...
Loop Capital downgrades FMC Corp. to Hold and lowers price target due to inventory challenges in critical markets. Concerns over ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.